Cg Oncology Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.49 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $68.35Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $6.1B Enterprise Value $6B Shares Outstanding 87.5M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary CG Oncology is a high-conviction, late-stage biopharmaceutical company uniquely positioned to redefine the treatment landscape for Non-Muscle Invasive Bladder Cancer (NMIBC). Its lead asset, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy that has demonstrated best-in-disease potential. With a robust cash runway of $1.1 billion extending through 2029, a clear regulatory path with BLA completion expected in Q4 2026, and highly encouraging combination data (92% CR in CORE-008 Cohort CX), CG Oncology represents a compelling investment opportunity with significant near-term catalysts. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$79.00 Mean target$91.08 High · most bullish analyst$108.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $79.0020% The FDA issues a Complete Response Letter (CRL) or requests additional clinical/CMC data during the BLA review, delaying approval by 12-18 months. Additionally, PIVOT-006 Phase 3 data fails to show a statistically significant risk reduction compared to surveillance, limiting cretostimogene's addressable market strictly to the high-risk niche and increasing long-term cash burn. Base CaseCentral scenario $91.0850% Matches the consensus meanCG Oncology successfully completes its BLA submission in Q4 2026, leading to FDA approval in late 2027. The commercial rollout proceeds steadily, targeting high-risk BCG-unresponsive patients. PIVOT-006 data supports clinical efficacy in intermediate-risk patients, and the company's $1.1 billion cash reserves comfortably fund operations through commercialization without requiring dilutive financing. Bull CaseUpside scenario $108.0030% Cretostimogene achieves rapid FDA approval in high-risk BCG-unresponsive NMIBC by early 2027, followed by a highly successful commercial launch leveraging established relationships with community urology clinics. Topline data from the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC demonstrates superior recurrence-free survival, unlocking a massive $1.2B+ market opportunity and establishing cretostimogene as the universal backbone therapy in bladder preservation. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |